SecBot SecBot

RDHL

RedHill Biopharma Ltd.
Nasdaq· Pharmaceutical Preparations· Inc. L3· CIK 0001553846 Biotech & Drug Discovery
$0.4230 +0.00 (+0.24%)
Oct 23 4:00 PM ET · prev $0.4220
Market cap
$3.8M
Nano cap
1 year
−74.2%
from $1.64 · Oct 24
30 days
−18.7%
from $0.5200
52-week range
$0.4220–1.64
−74% from high · low Oct 22
Avg volume 20D
936.7K
Oct 8 spike 15.75M
Short interest
211.2K
≈3.5% of shares · −10.2%
Days to cover
1.6
at average volume
Insider net
-$4.4K
0 buyers · 1 seller · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
20
analyzed by SecBot
SecBot read MIXED 11 reports · 90 days
Balance 2 bearish · 2 bullish · 7 neutral oldest → newest, height = score
Avg score ·High conf. 9/11
Strongest BEARISH RedHill Biopharma filed a 6-K and prospectus supplement to increase the maximum aggregate offering amount…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $4.4K.

  • InstitutionsMIXED

    Q2 2026: 3 added (0 new), 1 trimmed or exited.

  • Short sellersSTEADY

    Short interest −10.2% to 211.2K shares. 1.6 days to cover, ≈3.5% of shares.

  • TrendDOWNTREND

    26% below its 50-day average. New closing low $0.4220 on Oct 22.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
ROYAL BANK OF CANADADOUBLED351—
CITADEL ADVISORS LLCDOUBLED65,321$55.2K
RHUMBLINE ADVISERSDOUBLED13,755$11.6K
UBS Group AGNEAR_EXIT100$85.00
RHUMBLINE ADVISERSADD5,116$3.8K
UBS Group AGDOUBLED826$615.00
RHUMBLINE ADVISERSADD2,678$2.8K
GROUP ONE TRADING LLCTRIM4$4.00

Quarterly 13F filings are due 45 days after each quarter ends.

Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 19, 2026
Contract
$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma
TEL AVIV, Israel and RALEIGH, N.C., Oct. 19, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty…
Aug 31, 2026
Trading halt
Halt Resumed: RDHL — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-08-31T13:42:19.000Z | Resumed 2026-08-31T13:47:19.000Z
Aug 31, 2026
Trading halt
Trading Halt: RDHL — LUDP (Volatility Trading Pause)
Redhill Biopharma ADR | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Aug 31, 2026
Trading halt
Halt Resumed: RDHL — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-08-31T13:36:51.000Z | Resumed 2026-08-31T13:41:51.000Z
Aug 31, 2026
Trading halt
Trading Halt: RDHL — LUDP (Volatility Trading Pause)
Redhill Biopharma ADR | Market: NASDAQ | Code: LUDP — Volatility Trading Pause

Insider ledger

Form 4
$0
bought · 0 insiders
$4.4K
sold · 1 insider
DateInsiderTypeValue
Oct 1, 2026
Raday Gilead
Chief Operating Officer
SELL$1.4K
Oct 1, 2026
Raday Gilead
Chief Operating Officer
EXERCISE27,560,000 sh
Jul 10, 2026
Raday Gilead
Chief Operating Officer
SELL$1.4K
Jul 10, 2026
Raday Gilead
Chief Operating Officer
EXERCISE28,150,000 sh
Apr 6, 2026
Raday Gilead
Chief Operating Officer
SELL$1.6K
Apr 6, 2026
Raday Gilead
Chief Operating Officer
EXERCISE30,780,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
211,200
shares short
-10.2%
vs prior settlement
1.6
days to cover
≈3.5%
of shares outstanding
Trading halts
Aug 31, 2026Volatility PauseResumed
Aug 31, 2026Volatility PauseResumed
Aug 31, 2026News PendingNot resumed
Aug 31, 2026News ReleasedNot resumed
Aug 31, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
RedHill Biopharma regained ex-North America rights to RHB-102 after terminating its license agreement with Hyloris…
6-K — Impact 3/10
Oct 19, 2026 SEC
RedHill Biopharma announced a $2.9 million NCI grant to the University of Oklahoma for clinical trials combining…
6-K — Impact 3/10
Oct 19, 2026 Press
RedHill's partner, the University of Oklahoma, received a $2.9 million NCI grant to fund Phase 1b/2 clinical trials of…
Impact 3/10
Oct 19, 2026 Contract
$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma
TEL AVIV, Israel and RALEIGH, N.C., Oct. 19, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RD
Oct 13, 2026 SEC
RedHill Biopharma filed a 6-K and prospectus supplement to increase the maximum aggregate offering amount under its…
6-K — Impact 6/10
Oct 1, 2026 Insider
Raday Gilead sold 14,310,000 shares
Chief Operating Officer @ $0.000100 ($1.4K)
Oct 1, 2026 Insider
Raday Gilead acquired via exercise 27,560,000 shares
Chief Operating Officer
Jul 10, 2026 Insider
Raday Gilead sold 14,130,000 shares
Chief Operating Officer @ $0.000100 ($1.4K)

SecBot reports

20 filings · 1 press releases · 3 bullish · 6 bearish · 2 mixed · 9 neutral
All RDHL filing & press-release reports (27)